Related Experiment Video
Updated: Jun 13, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
A case of Paget's disease in hemodialysis
G Cianciolo1, G La Manna, I Capelli
1Nephrology Dialysis and Renal Transplantation Unit, S. Orsola University Hospital, Bologna, Italy.
Insights
This case study details the first reported instance of Paget's disease in a hemodialysis patient. A combination therapy of clodronate, cinacalcet, and paracalcitol proved effective in managing this rare condition.
Area of Science:
- Nephrology and Endocrinology
- Bone Metabolism and Mineral Disorders
Background:
- Paget's disease is a prevalent bone disorder characterized by excessive bone turnover.
- Chronic kidney disease (CKD) significantly disrupts bone mineral metabolism, electrolyte balance, and parathyroid hormone (PTH) homeostasis.
- The co-occurrence of Paget's disease and CKD presents unique clinical challenges.
Observation:
- A hemodialysis patient presented with Paget's disease, a condition rarely seen in this population.
- The patient also exhibited secondary hyperparathyroidism, a common complication in CKD.
- This marks the first documented case of Paget's disease in a patient undergoing hemodialysis.
Findings:
- A combined therapeutic approach using clodronate, cinacalcet, and paracalcitol was successfully implemented.
- The 12-month follow-up demonstrated the safety and efficacy of this multi-drug regimen.
- Treatment outcomes were assessed using standard bone turnover markers and levels of OPG, RANKL, IL-6, and MCSF.
Implications:
- This study suggests a viable therapeutic strategy for managing Paget's disease in hemodialysis patients.
- The findings highlight the importance of monitoring bone metabolism in CKD patients.
- Further research into the combined effects of these agents on bone pathophysiology markers is warranted.
Abstract:
Paget's disease is the second most common bone disease after osteoporosis and causes an excessive bone turnover. Moreover, chronic kidney failure causes an impairment of bone mineral metabolism and electrolytes and PTH homeostasis. As far as we know, this is the first reported case of Paget's disease in a hemodialysis patient: the patient was also affected by secondary hyperparathyroidism and was successfully treated with clodronate, cinacalcet and paracalcitol. The safety and efficacy of this combined therapy was periodically revised in a 12-month follow-up considering the common markers of bone turnover as well as the dosage of OPG, RANKL, IL-6 and MCSF, involved in the pathophysiology of Paget's disease.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Peritoneal Dialysis III: Nursing Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Dialysis
